Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses

PLoS Neglected Tropical Diseases

Volumn 6, Issue 5, 2012, Pages

  Chiang, Chen Yi ^a   Huang, Ming Hsi ^a   Hsieh, Chun Hsiang ^a   Chen, Mei Yu ^a   Liu, Hsueh Hung ^a   Tsai, Jy Ping ^a   Li, Yi Shiuan ^a   Chang, Ching Yun ^a   Liu, Shih Jen ^a,b   Chong, Pele ^a,b   Leng, Chih Hsiang ^a,b   Chen, Hsin Wei ^a,b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; CPG OLIGODEOXYNUCLEOTIDE; DENGUE 1 ENVELOPE DOMAIN III VACCINE; DENGUE VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; PELC; UNCLASSIFIED DRUG; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; OIL; OLIGODEOXYRIBONUCLEOTIDE; RECOMBINANT VACCINE; SUBUNIT VACCINE; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; DENGUE; DENGUE VIRUS 1; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; MOLECULAR CLONING; MOUSE; NANOEMULSION; NONHUMAN; PROTEIN DOMAIN; PROTEIN PURIFICATION; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DENGUE VIRUS; GENETICS; IMMUNOLOGY; MONONUCLEAR CELL; SECRETION; SPLEEN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DENGUE VACCINES; DENGUE VIRUS; IMMUNOGLOBULIN G; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; OILS; OLIGODEOXYRIBONUCLEOTIDES; SPLEEN; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 84863648647     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001645     Document Type: Article

References (39)

1. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, et al. (2010) Dengue: a continuing global threat. Nat Rev Microbiol 8: S7-16.
2. Halstead SB, (2007) Dengue. Lancet 370: 1644-1652.
3. Coller BA, Clements DE, (2011) Dengue vaccines: progress and challenges. Curr Opin Immunol 23: 391-398.
4. Schmitz J, Roehrig J, Barrett A, Hombach J, (2011) Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine 29: 7276-7284.
5. Whitehead SS, Blaney JE, Durbin AP, Murphy BR, (2007) Prospects for a dengue virus vaccine. Nat Rev Microbiol 5: 518-528.
6. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, et al. (1997) Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 3: 866-871.
7. Hung J-J, Hsieh M-T, Young M-J, Kao C-L, King C-C, et al. (2004) An External Loop Region of Domain III of Dengue Virus Type 2 Envelope Protein Is Involved in Serotype-Specific Binding to Mosquito but Not Mammalian Cells. J Virol 78: 378-388.
8. Crill WD, Roehrig JT, (2001) Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells. J Virol 75: 7769-7773.
9. Hiramatsu K, Tadano M, Men R, Lai C-J, (1996) Mutational Analysis of a Neutralization Epitope on the Dengue Type 2 Virus (DEN2) Envelope Protein: Monoclonal Antibody Resistant DEN2/DEN4 Chimeras Exhibit Reduced Mouse Neurovirulence. Virology 224: 437-445.
10. Roehrig JT, Bolin RA, Kelly RG, (1998) Monoclonal Antibody Mapping of the Envelope Glycoprotein of the Dengue 2 Virus, Jamaica. Virology 246: 317-328.
11. Roehrig JT, Risi PA, Brubaker JR, Hunt AR, Beaty BJ, et al. (1994) T-Helper Cell Epitopes on the E-Glycoprotein of Dengue 2 Jamaica Virus. Virology 198: 31-38.
12. Thullier P, Demangel C, Bedouelle H, Megret F, Jouan A, et al. (2001) Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol 82: 1885-1892.
13. Trirawatanapong T, Chandran B, Putnak R, Padmanabhan R, (1992) Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody. Gene 116: 139-150.
14. Guzman MG, Hermida L, Bernardo L, Ramirez R, Guillen G, (2010) Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines 9: 137-147.
15. Bernardo L, Izquierdo A, Alvarez M, Rosario D, Prado I, et al. (2008) Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res 80: 194-199.
16. Bernardo L, Pavon A, Hermida L, Gil L, Valdes I, et al. (2011) The two component adjuvant IC31(R) potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice. Vaccine 29: 4256-4263.
17. Block OK, Rodrigo WW, Quinn M, Jin X, Rose RC, et al. (2010) A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice. Vaccine 28: 8085-8094.
18. Chen HW, Liu SJ, Liu HH, Kwok Y, Lin CL, et al. (2009) A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. Vaccine 27: 1400-1409.
19. Chiang CY, Liu SJ, Tsai JP, Li YS, Chen MY, et al. (2011) A novel single-dose dengue subunit vaccine induces memory immune responses. PLoS One 6: e23319.
20. Leng CH, Chen HW, Chang LS, Liu HH, Liu HY, et al. (2010) A recombinant lipoprotein containing an unsaturated fatty acid activates NF-kappaB through the TLR2 signaling pathway and induces a differential gene profile from a synthetic lipopeptide. Mol Immunol 47: 2015-2021.
21. Leng CH, Liu SJ, Tsai JP, Li YS, Chen MY, et al. (2009) A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect 11: 288-295.
22. Valdes I, Bernardo L, Gil L, Pavon A, Lazo L, et al. (2009) A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 394: 249-258.
23. Zulueta A, Martin J, Hermida L, Alvarez M, Valdes I, et al. (2006) Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res 121: 65-73.
24. Huang MH, Chou AH, Lien SP, Chen HW, Huang CY, et al. (2009) Formulation and immunological evaluation of novel vaccine delivery systems based on bioresorbable poly(ethylene glycol)-block-poly(lactide-co-epsilon-caprolactone). J Biomed Mater Res B Appl Biomater 90: 832-841.
25. Huang MH, Huang CY, Lien SP, Siao SY, Chou AH, et al. (2009) Development of multi-phase emulsions based on bioresorbable polymers and oily adjuvant. Pharm Res 26: 1856-1862.
26. Huang MH, Huang CY, Lin SC, Chen JH, Ku CC, et al. (2009) Enhancement of potent antibody and T-cell responses by a single-dose, novel nanoemulsion-formulated pandemic influenza vaccine. Microbes Infect 11: 654-660.
27. Huang MH, Lin SC, Hsiao CH, Chao HJ, Yang HR, et al. (2010) Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice. PLoS One 5: e12279.
28. Stemmer WPC, Crameri A, Ha KD, Brennan TM, Heyneker HL, (1995) Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides. Gene 164: 49-53.
29. Guzman MG, Rodriguez R, Hermida L, Alvarez M, Lazo L, et al. (2003) Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am J Trop Med Hyg 69: 129-134.
30. Robert Putnak J, Coller BA, Voss G, Vaughn DW, Clements D, et al. (2005) An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 23: 4442-4452.
31. Simmons M, Porter KR, Hayes CG, Vaughn DW, Putnak R, (2006) Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J Virol 80: 9577-9585.
32. Velzing J, Groen J, Drouet MT, van Amerongen G, Copra C, et al. (1999) Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines. Vaccine 17: 1312-1320.
33. Mehlhop E, Ansarah-Sobrinho C, Johnson S, Engle M, Fremont DH, et al. (2007) Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2: 417-426.
34. Kool M, Soullie T, van Nimwegen M, Willart MA, Muskens F, et al. (2008) Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 205: 869-882.
35. Kool M, Willart MA, van Nimwegen M, Bergen I, Pouliot P, et al. (2011) An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity 34: 527-540.
36. Kuroda E, Ishii KJ, Uematsu S, Ohata K, Coban C, et al. (2011) Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity 34: 514-526.
37. Serre K, Benezech C, Desanti G, Bobat S, Toellner KM, et al. (2011) Helios is associated with CD4 T cells differentiating to T helper 2 and follicular helper T cells in vivo independently of Foxp3 expression. PLoS One 6: e20731.
38. Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, et al. (2004) Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol 78: 2701-2710.
39. Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, et al. (2009) A protective role for dengue virus-specific CD8+ T cells. J Immunol 182: 4865-4873.